Introduction
The chimeric BCR/ABL fusion mRNA can be found in CML (in Ͼ95% of cases) and ALL (in approximately 25% of cases in adults, 1 2-5% of cases in children 2 or very rarely also in other hematological diseases. It is by far the worst prognostic factor in ALL with a 5-year survival rate of BCR/ABL-positive patients treated by conventional chemotherapy ranging from 0 to 15%. 2, 3 Currently, aggressive therapy regimens including allogeneic blood stem cell or bone marrow transplantation offer the only realistic chance for cure. The BCR/ABL fusion gene results from the usually reciprocal chromosomal translocation t(9;22)(q34;q11) (Philadelphia chromosome). 4 It leads to the fusion of two genes, ABL on chromosome 9, a cellular proto-oncogene coding for a tyrosine kinase, and BCR on chromosome 22, coding for a serine kinase. In BCR/ABL-positive ALL approximately 70% of cases show a chromosomal breakpoint between BCR exons 1 and 2 (m-bcr region), in the remaining 30% the breakpoint maps between exons 13 and 15 historically named b2-b4 (M-bcr region), while m-bcr breakpoints are very rarely found in CML. In the ABL gene locus the breakpoint is nearly always located 5Ј upstream of exon 2. Rarely 'atypical' transcripts (other than e1a2, b2a2, b3a2) have been reported, suggesting chromosomal breakpoints outside M-bcr or m-bcr (leading to transcripts such as c3a2 5, 6 or 3Ј downstream of ABL exon 2, 7 with the latter mostly leading to an in-frame fusion of ABL exon 3 with BCR. 8 The frequency of such atypical transcripts is estimated at 2-4% of CML and BCR-ABL-positive ALL cases. 7 RT-PCR is the method of choice in detecting the BCR/ABL fusion gene. It confirms the diagnosis of CML and ALL and is used for therapy stratification in ALL 3 as well as for assessment of minimal residual disease and follow-up examinations after allogeneic transplantation. Standard cytogenetics do not have comparable sensitivity, and metaphases are often too infrequent for valid cytogenetic data to be obtained from patient samples. FISH (fluorescence in situ hybridization) likewise fails to achieve the sensitivity of PCR.
Here we describe the results of an interlaboratory test for RT-PCR-based BCR/ABL diagnostics which was performed in two consecutive parts. In the first part cloned BCR/ABL DNA samples with the most common BCR/ABL fusion transcripts in various concentrations were sent to the participants to be analyzed by PCR. In the second part of the test, cell samples with various concentrations of BCR/ABL-positive cell lines were sent to the participants to evaluate the complete method. This enabled two independent rounds of interlaboratory test series.
Materials and methods

Test design
The project was initiated and organized by the Dept of Hematology (Med Klinik III) at the Freie Universität Berlin. Participants were several laboratories from Germany, among them mainly departments of hematology or pediatric hematology of university hospitals. All participants are listed in alphabetical order in the authors list of this publication (laboratories 1-20 participated in both parts of the test, whereas 21-27 only participated in the first part). All participants received a code number from C1 to C30, and the synopsis of the test results was announced anonymously to all participants. Twenty-three laboratories gave permission to publish their laboratory methods on the Internet (the collection is available as an Adobe Acrobat PDF-file under the Internet address http://www.medizin.fu-berlin.de/haema/methods.pdf).
Cloning of BCR/ABL transcripts
The three most prevalent BCR/ABL transcripts (e1a2, b2a2, b3a2) were cloned from archived patient material as follows: after reverse transcription of extracted total RNA. First-strand cDNA synthesis kit (Pharmacia, Freiburg, Germany), primer 5Ј-TGTGC TTCATGGTGATGTCCGTGC-3Ј), a PCR product was generated (primer 5Ј-ACTTGTCGTAGTTGGGGGACA-CACCA-3Ј in combination with either 5Ј-GTACCAGCCCTAC-CAGA GCATCTACG-3Ј for the e1a2 transcript or 5Ј-GCGAA-CAAGGGCAGCAAGGCTACG-3Ј for the major BCR breakpoint, 45 cycles of 30 s at 94°C, 30 s at 63°C, 90 s at 72°C) and ligated into the TA cloning kit (pCR II, pCR 2.1) vector (Invitrogen, Groningen, The Netherlands) following the recommended protocol. E. coli DH5␣ were transformed with an aliquot of the ligation reaction mix. The nucleotide sequences of the three cloned inserts are accessible under the following EMBL/Genbank/DDBJ accession numbers: AJ131466 (b3a2), AJ131467 (b2a2), AF113911 (e1a2).
BCR/ABL-positive cell lines
The following cell lines were used: K-562, 9 expressing the b3a2 and in much lower quantity also the e1a2 transcript; 10 BV-173, expressing the b2a2 transcript 11 and in much lower quantity also the e1a2 transcript 12 and SD-1, expressing the e1a2 transcript. 13 K-562 was obtained from U Erben, Freie Universität Berlin, the other cell lines were obtained from the Dept of Human and Animal Cell Cultures, Braunschweig, Germany (DSMZ accession numbers ACC 20, ACC 366, respectively). The cells were cultured in 250-ml flasks using standard cell culture techniques (90% RPMI + 10% FBS, 5% CO 2 ) with regular microscopic inspection and passaging of cells to ensure cell viability.
Organization of the interlaboratory test and preparation of samples
RT-PCR-based BCR/ABL analysis can be divided into three steps: first RNA isolation from patient material (usually peripheral blood or bone marrow aspirate), second reverse transcription of RNA into cDNA (hereafter referred to as 'RT reaction') and third PCR reaction with the generated cDNA.
Leukemia Accordingly, the interlaboratory test was organized in two parts. The first part evaluated quality and sensitivity of the PCR reaction. The three most prevalent BCR/ABL transcripts were cloned from patient material as described above. Serial dilutions of the three most prevalent BCR/ABL transcripts (see above) were prepared in ultrapure water. Genomic leukocyte DNA was prepared from two healthy controls and photometrically adjusted to a concentration of approximately 20 ng/l. A defined volume of plasmid solution was added to 2 ml genomic DNA solution, mixed well, and aliquoted in 50 l portions in 1.5 ml Eppendorf tubes. For each transcript six probes were prepared with the following plasmid concentrations (in parentheses the equivalent of BCR/ABL-cDNA molecules): 100 pg/l (2 × 10 7 /l); 10 pg/l (2 × 10 6 /l); 1 pg/l (2 × 10 5 /l); 100 fg/l (2 × 10 4 /l); 10 fg/l (2 × 10 3 /l). Altogether 22 DNA samples were sent to each participant (6 × e1a2, 6 × b2a2, 6 × b3a2, 4 × negative, ie genomic DNA solutions).
The second part evaluated quality and sensitivity of the entire analysis. Cell samples were prepared as follows: BCR/ABL-positive cell lines were cultured as described above. Leukocytes were prepared from buffy coats obtained from healthy blood donors in the local Department of Transfusion Medicine. The leukocytes were isolated from the buffy coat using Ficoll gradient centrifugation, washed twice with PBS and redissolved in FBS. The cell number was determined with a Coulter counter (Coulter Electronics, Krefeld, Germany) and adjusted to 2 × 10 7 /ml. BCR/ABL-positive culture cells were prepared in the same way, adjusted to an appropriate concentration (determined with the Coulter counter), and a defined amount was added to the buffy coat leukocyte preparation. Ten percent DMSO was added, the solution was mixed well and aliquoted into 1 ml cryotubes (Nunc, Rochester, MA, USA). The samples were carefully frozen in liquid nitrogen and kept stored until shipment. 
Shipment of samples
In the first part of the interlaboratory test, DNA samples were sent to the participants by standard mail. In the second part, the cell samples were sent to them on dry ice. The majority of cell samples were sent via express mail (ensuring a delivery within 24 h). An appropriate volume of dry ice for more than 2 days shipment was added to each packet to prevent a thawing of frozen cell samples. Participants were instructed to store the DNA samples at 4°C and the cell samples in liquid nitrogen (or, if not available, at −80°C) immediately on arrival.
Results and discussion
DNA samples
In the first part of the interlaboratory test, 30 laboratories received DNA samples with a defined amount of BCR/ABL DNA. Twenty-seven (90%) submitted their results within a period of 2. months (results in Table 1 ). During evaluation it became clear that one participant (C13) had used unsuitable primers for detection of the m-bcr transcripts. The m-bcr results of this participant were therefore not included in the overall evaluation. Participant C26 ran a nested PCR using an outer PCR primer that annealed in BCR exons 10/11, a region that was not present in the shipped plasmids. Nevertheless, C26 achieved a good sensitivity. Altogether 594 (22 × 27) samples were analyzed. Four-hundred and eighty-six samples (18 × 27) contained BCR/ABL transcripts ('positive samples'), and 108 samples (4 × 27) contained only genomic DNA ('negative samples'). There were 10 false negative results (corresponds to 2.1% of all positive samples) which were distributed among three participants. One participant (C7) had two ambiguous results. There were 11 false positive results (detection of BCR/ABL transcripts in samples, containing only genomic DNA). This corresponded to 10.2% of all negative samples. These false positive results were distributed among eight participants. In 11 cases wrong transcripts were detected (e1a2 instead of b2a2 or b3a2, b3a2 or b2a2 instead of e1a2). Five participants had wrong transcripts. Some participants could detect another transcript only in the nested PCR. This could be traced back to contaminations in the original plasmid solutions used to prepare the samples (b3a2 in e1a2, e1a2 in b2a2 and e1a2 in b3a2). Quantification of transcripts with real-time PCR by participant C28 showed that the concomitant transcript was present in a copy number of less than 5 × 10 −5 in proportion to the main transcript. These additional transcripts (in italic letters in Table  1 ) were therefore not considered further and regarded as correct results.
In summary, 14.8% of all participants had false negative or ambiguous results, 29.6% had false positive results, 18.5% had detected wrong transcripts. Altogether, 10 (37.0% of all) participants had at least one false negative or ambiguous result, at least one false positive result and/or at least one wrong transcript detected.
As outlined above, approximately 60% of the participants met the criteria for 100% specificity (no wrong transcripts, no false positive result) and 100% sensitivity (detection limit 2000 BCR/ABL-cDNA-equivalents/l reached). The results showed that lack of sensitivity was not the predominant problem, approximately 85-90% of all participants met the sensitivity requirements. Only one participant showed a clearly insufficient sensitivity, comprising seven of the 10 false negative results of the whole series, the other three false negative results were 'sporadic', suggesting pipetting errors or similar causes. The main problems turned out to be wrong transcripts (18.5% of all participants) and false positive results (29.6% of all participants). False positive results usually cannot be explained by inappropriate PCR conditions; obviously they result from contamination of the PCR reaction mix, most likely through PCR products from previous PCR reactions. Wrong transcripts may result from contamination as well, and in part they may simply be explained by misinterpretation of agarose gel results. Nevertheless they should not be underestimated, since follow-up monitoring of BCR/ABL-positive patients is sometimes done with 'transcript-specific' PCRs, eg an optimized PCr that is only able to detect the major breakpoint transcript. Thus, a wrong initial diagnosis, such as 'Mbcr-positive' instead of m-bcr may be severely misleading.
Cell samples
In the second part of the test, 23 laboratories received cell samples with defined concentrations of BCR/ABL-positive cells (preparation as described above). Twenty laboratories (87%) returned their results within a period of 2. months (results in Table 2 ). All of them had also participated in the first part of the test. Three laboratories required a second charge of selected samples to be re-analyzed. Eighteen samples were analyzed twice in this way. One sample (0.3%, BV-173) could not be analyzed (RNA extraction failed) and was excluded from the evaluation. Counting the doubly analyzed samples once, 319 (20 × Two participants could detect all dilutions and had no false results. Another participant could also detect all dilutions without any false result except in one sample (BV-173 1:100) where RNA extraction failed. Two participants had a clear general lack of sensitivity in both m-bcr and M-bcr (6/7 false negative results, respectively). The BV-173 1:200 dilution unexpectedly had many false negative results (more than the 1:2000 dilution), probably because of difficulties in RNA extraction due to cell clumping (reported by some participants).
While analyzing the results obtained with cell samples, one has to bear in mind that the rate of expression of BCR/ABLtranscripts is quite different in the cell lines used here. Expression of the BCR/ABL fusion gene is extraordinarily high in K-562, lower in BV-173 and lowest in SD-1. More than twice as many false negative results were obtained in m-bcrcontaining than in M-bcr-containing samples were obtained, although the M-bcr samples comprised 2/3 of the positive samples. This result should not simply be interpreted as a general lack of sensitivity in detecting the minor breakpoint transcript. It may merely reflect the much lower expression of BCR/ABL-transcripts in the SD-1 cell line. In summary, all participants detected the lowest dilutions (1:20/25), eight participants (40%; C3, C4, C5, C12, C16, C22, C25, C28) could detect all dilutions up to 1:2000/2500 without having false positive results or false transcripts, and three of them (15%; C4, C16, C25) were able to detect dilutions up to 1:20 000.
The wrong transcripts and false positive results can be explained by contamination or misinterpretations of results, as outlined above. The question of interest is how the differences in sensitivity can be explained.
PCR method
A comparative analysis of the PCR methodology revealed that 24 participants regularly used a nested or semi-nested PCR. One of them (C7) used the nested PCR for M-bcr only if the result from the first PCR was ambiguous. Two participants (C18, C29) did not use a nested PCR. One participant (C4) used a single-round PCR 14 for diagnostic samples and a nested PCR for follow-up and MRD investigations. Also, a great variety of primer pairs was used. The most frequently used primer sequences were those published by Maurer et al 1 with or without the modifications by Lee et al 15 (participants C3, C6, C8, b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2
(100 pg/l) e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 6 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 -e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 0 e1a2 e1a2 e1a2 e1a2 b2a2
(1 pg/l) b2a2 7 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2
(1 pg/l) e1a2 e1a2 8 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 b3a2 e1a2 e1a2 e1a2 -e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2
(100 pg/l) b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b2a2 b2a2 9 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 0 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2
(100 fg/l) e1a2 10 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 0 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2
(100 pg/l) b3a2 b3a2 b3a2 b3a2 b3a2 b2a2 b3a2 b3a2 b3a2 b3a2 0 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2 b3a2
(10 fg/l) ela2 b2a2 20 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 (e1a2) e1a2 e1a2 e1a2 e1a2 e1a2 b2a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 0 e1a2 e1a2 e1a2 e1a2 e1a2 100 fg/l) b3a2 21 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 0 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2 b2a2
(1 fg/l) 22 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 b3a2 e1a2 e1a2 e1a2 b2a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 e1a2 b3a2 C10, C19, in part C22), Cross et al 14 (participants C4, C18) or Hochhaus et al 16 (participants C4, C30). The results of the first part showed that good sensitivity could be achieved with DNA samples in the great majority of cases under the various PCR conditions. Thus no single primer system is clearly preferable with respect to sensitivity. From the results it appears as if the nested PCR would yield no advantage over the singleround PCR. However, the nested PCR usually leads to cleaner PCR products with fewer side products than the single-round PCR, and this is especially true for PCR reactions with cDNA as sample material instead of pure DNA, as used here and for low target gene concentrations. Therefore we do not generally recommend the use of a single-round PCR although it may be advantageous especially in CML at diagnosis, where lack of material or low target gene concentrations are not a problem.
Primer location
Primers should be located in an exon that is not too far away from the site of the chromosomal breakpoint. In most cases the ABL breakpoint is located 5Ј upstream of exon 2. However, primers with location in exon 3 have the advantage of also detecting some of the above-mentioned atypical transcripts where ABL exon 3 is fused to BCR.
RNA isolation
Most of the participants who took part in the second part of the test used commercial kits for RNA extraction. Only one laboratory (C5) used a kit for mRNA extraction, the others prepared total RNA. We conclude from the results that there is no apparent need to use mRNA isolation, good results can be obtained with isolation of total RNA. Tables 1 and 2 show that good results can be obtained with various methods.
Reverse transcription
Most participants of the second part of the test used random hexamers (11 participants, 55%), only one (5%) used oligodT primers. Both methods are satisfactory with regard to the RNA integrity control, since in an aliquot of the RT reaction mix can be used for both the BCR/ABL PCR and the control PCR for RNA integrity, and in principle any gene can be used for integrity control. Poly-dT oligomers appear less suited in this case because of the large distance (some 1000 nucleotides) between poly-A tail and ABL exon 2. Specific primers were used by eight participants (40%). Specific primers usually yield higher transcription efficiency, since they preferentially transcribe the gene of interest. However, if some gene other than the normal ABL gene is used for positive control, a second (specific or oligo-dT) primer has to be added to the RT reaction mix to transcribe this gene (as has been done by participant C12). A variety of different enzymes were used for reverse transcription (see the laboratory methods published on the Internet), and no single enzyme was clearly superior to the others.
Negative and positive controls
The majority of participants in the second part of the test (14, 70%) used RNA or cDNA from (diluted or non-diluted) Leukemia BCR/ABL-positive cell lines as positive controls, others used BCR/ABL-positive patient samples (3, 7.5%). While using cell lines, it must be borne in mind that many BCR/ABL-positive cell lines, eg K-562, BV-173, NALM-1, LAMA-84, are derived from CML patients in blast crisis and usually show an extraordinarily strong expression of BCR/ABL transcripts. We therefore strongly recommend diluting cell lines appropriately in BCR/ABL-negative cells when using them as positive controls.
In addition, the integrity of the RNA has to be ensured in every patient sample. 18 The majority of participants used either ABL (10 participants, 50%) or BCR (one participant, 5%) for RNA integrity control.
Summary and conclusions
The first part of this interlaboratory test suggests that PCR sensitivity is satisfactory in approximately 90% of the participating laboratories, but that regular quality controls are necessary to ensure specificity. The results in the second part of the test allow certain conclusions regarding the efficiency and quality of RNA isolation and reverse transcription. Since the vast majority of participants showed sufficient sensitivity in the PCR, inadequate sensitivity in the analysis of cell samples should be ascribed primarily to a lack of efficiency in RNA isolation and/or reverse transcription. This may not necessarily be the case, however, since a very sensitive PCR with a detection limit far below the 2000 transcripts/l tested here can partially compensate for an inefficient RNA isolation and/or reverse transcription.
Suggestions for BCR/ABL RT-PCR:
(1) For first time diagnosis primers should be capable of amplifying both m-bcr and M-bcr transcripts and the most important atypical transcripts (b2a3, b3a3, c3a2). BCR primers should be located in BCR exon 13 (b2 in old nomenclature) or 5Ј upstream for the major breakpoint and in BCR exon 1 for the minor breakpoint. ABL primers should be located in ABL exon 3 so that atypical transcripts lacking ABL exon 2 (b2a3, b3a3) can also be detected. Regarding sensitivity, we suggest that a 1:1000 dilution of K-562/BV-173/SD-1 cells should be detectable by RT-PCR for samples at diagnosis. The sensitivity should not be too high, since this increases the possibility of false positive results at initial diagnosis due to contamination and could prove disastrous. (2) Follow-up or MRD investigations can be done with optimized transcript-specific primers. Regarding sensitivity, we suggest that 2000 BCR/ABL cDNA molecules should be detectable in PCR, while an at least 1:10 4 dilution of K-562, BV-173 or SD-1 cells should be detectable by the whole procedure. The significance of this limit still remains to be evaluated in clinical studies. Recent pediatric studies based on TCR and immunoglobulin rearrangement MRD detection 18 have established this level as suitable. However, these studies were based on DNA analysis and are therefore not fully comparable to the RNA-based analytic situation. (3) For reverse transcription we recommend the use of random hexamers or specific primers. Specific primers usually show a better transcription efficiency than random hexamers, but as has been explained above, the choice of the RNA integrity control is more difficult unless the cellular ABL gene is used for control. (4) It is not necessary to use mRNA isolation, since good results can be obtained with isolation of total RNA.
(5) The PCR reaction should always include a positive and a negative control as outlined under 'negative and positive controls' above and an (external or internal) RNA integrity control. Suitable control genes for ensuring RNA integrity are ABL, BCR or other moderately expressed genes that lack pseudogenes. 17 The amplified control should yield a larger PCR product than the BCR/ABL transcripts.
In the future, MRD investigations will be based mainly on fluorimetric real-time PCR techniques. This will allow a better quantification of MRD. Other questions that will have to be discussed include the choice of fluorescence probes, reference genes, and cycler programs. However, several of the questions discussed here, such as choice of primers, mode of reverse transcription and controls also apply in this field. Standardization approaches have recently been developed for primers and RT-PCR reaction conditions. 19 The results of this interlaboratory test show that a high analytic standard has been reached in the majority of participating laboratories. However, the fact that 10.2% were false positive in the first and 6.3% in the second round appears somewhat alarming, since such results may lead to serious errors in making therapy decisions. Possibilities for avoiding false positive results include the additional use of another method for detecting BCR/ABL (eg Western blot, FISH, or standard cytogenetics) to confirm the PCR. As stated in the introduction, these methods are not as sensitive as the PCR and thus cannot be considered suitable for MRD investigations. A second control RT-PCR, performed in another laboratory with different primer sequences not capable of amplifying contamination by PCR products from the first PCR, could also be useful for avoiding false positive results. The most important conclusion that should be drawn from the results of this interlaboratory test is the strong recommendation that all laboratories concerned with this kind of PCR-based diagnostics should be subjected to regular external quality controls.
